氯吡格雷血小板反应性与心血管应答的全基因组关联研究:国际氯吡格雷药物基因组学联盟研究
该研究对2750例欧洲 ancestry 个体进行全基因组关联研究,以ADP诱导的血小板反应性和主要心脑血管事件为结局。结果显示CYP2C19*2是氯吡格雷血小板反应性最强的遗传决定因素,校正后无其他SNP达全基因组显著性;临床结局整体无显著关联,但在冠状动脉疾病、PCI和急性冠脉综合征亚组中发现SCOS5P1、CDC42BPA和CTRAC1的突变达全基因组显著性。
要点
- CYP2C19*2是氯吡格雷血小板反应性最强的遗传决定因素。
- 校正CYP2C19*2后,未发现其他SNP与血小板反应性达全基因组显著关联。
- 临床结局亚组中SCOS5P1、CDC42BPA和CTRAC1突变显示全基因组显著性,需进一步验证。
核心结论
- CYP2C19*2是氯吡格雷治疗患者血小板反应性最强的遗传决定因素。
- 在临床结局亚组中识别出三个新的遗传关联,分别提示对相应结局的潜在影响。
研究设计与样本
- 研究采用全基因组关联研究(GWAS),纳入2750例欧洲 ancestry 个体的DNA。
- 以二磷酸腺苷诱导的血小板反应性和主要心脑血管事件为结局参数。
主要发现
- 血小板反应性GWAS显示CYP2C19*2强信号(P值=1.67e-33)。
- 校正CYP2C19*2后,无其他单核苷酸多态性达全基因组显著性。
- 心血管死亡、心肌梗死或卒中联合终点事件率为5.0%,心血管死亡或心肌梗死联合终点事件率为4.7%,整体GWAS无显著结果。
- 在冠状动脉疾病、经皮冠状动脉介入和急性冠脉综合征亚组中,SCOS5P1、CDC42BPA和CTRAC1突变达全基因组显著性(最低P值分别为1.07e-09、4.53e-08和2.60e-10)。
临床怎么用
- 临床可关注CYP2C19*2检测以评估氯吡格雷血小板反应性,但其他遗传变异对临床结局的常规应用证据尚不充分。
局限性
- 研究仅纳入欧洲 ancestry 个体,结果外推至其他人群需谨慎。
- 临床结局亚组中的新关联需在独立人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss-of-function alleles play an important role in this response, but account for only a small proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify other genetic determinants of clopidogrel pharmacodynamics and clinical response. A genomewide association study (GWAS) was performed using DNA from 2,750 European ancestry individuals, using adenosine diphosphate-induced platelet reactivity and major cardiovascular and cerebrovascular events as outcome parameters. GWAS for platelet reactivity revealed a strong signal for CYP2C19*2 (P value = 1.67e-33). After correction for CYP2C19*2 no other single-nucleotide polymorphism reached genomewide significance. GWAS for a combined clinical end point of cardiovascular death, myocardial infarction, or stroke (5.0% event rate), or a combined end point of cardiovascular death or myocardial infarction (4.7% event rate) showed no significant results, although in coronary artery disease, percutaneous coronary intervention, and acute coronary syndrome subgroups, mutations in SCOS5P1, CDC42BPA, and CTRAC1 showed genomewide significance (lowest P values: 1.07e-09, 4.53e-08, and 2.60e-10, respectively). CYP2C19*2 is the strongest genetic determinant of on-clopidogrel platelet reactivity. We identified three novel associations in clinical outcome subgroups, suggestive for each of these outcomes.
引用
- Verma SS, Bergmeijer TO, Gong L, et al. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clin Pharmacol Ther. 2020. PMID: 32472697. doi:10.1002/cpt.1911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。